Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH

Argo Biopharma Completes First Patient Dosing for Phase II Clinical Trial in Chronic Hepatitis B

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Argo Biopharma Receives IND Approval for Phase II Clinical Trial of Promising siRNA-PEG-IFNα Combination Therapy in Chronic Hepatitis B

Argo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B

Argo Biopharma’s Novel siRNA Therapeutic BW-20507 Granted Breakthrough Therapy Designation in China for Chronic Hepatitis B Virus Infection